Earnings season is handing AI the mic, and the market is already deciding who gets to keep it

On 18 August 2026, Cogstate published its full-year 2026 slides: record contract value, a renewed push into AI, and a revenue line that came in below the street's number. Shares moved on the miss, not the contracts. Hours earlier, Pro Medicus told a different story at the other end of the Australian healthtech corridor: record H2 2026, share price up 12.4% in the session, the kind of clean print that lets a board walk onto a podium without flinching.

This publication's reading: the market is no longer rewarding AI ambition on its own. It is rewarding AI ambition that is already showing up in the revenue line. Anything else gets the discount.

The two prints, side by side

Cogstate's investor presentation flagged record contract value for fiscal 2026 and explicit AI investment commitments, alongside a revenue result below consensus. The transcript of the company's earnings call made the tension explicit: management spoke to a forward pipeline that justified the AI spend, while analysts on the line pressed on the near-term shortfall. The shares, accordingly, sold the print and bought the deck.

Pro Medicus's H2 2026 transcript, by contrast, was the kind of document a chief financial officer frames and hangs on the wall. Record revenue, the company said, with the share move doing the rest. The piece Investing.com ran alongside the transcript asked the obvious question and gave the obvious answer: the stock was up because the numbers were up.

The point is not that one company is good and the other is bad. It is that two healthtech names, operating in overlapping end markets and selling to overlapping hospital and clinical-trial customers, finished the same Tuesday with two completely different investor verdicts. The difference was timing: Pro Medicus's AI investments are visible in revenue today; Cogstate's are still a forward story.

What "record contracts" actually means

The phrase deserves a closer read. "Record contracts" in a deck is a sales-line metric: the total value of agreements signed in a period, weighted by probability or term length depending on the company's accounting choices. It is a leading indicator, not a realised one. Revenue is the lagging indicator. The market knows which one feeds next year's dividend and which one feeds the narrative.

That is why the transcripts matter more than the slides. Cogstate's earnings call had to do work the deck could not: translate a strong bookings number into a credible path to revenue, while absorbing the disappointment of the print. Pro Medicus's transcript could simply describe what had already happened. One was a sales pitch, the other was a recap.

This publication finds that investors are now pricing the gap between those two registers, and the gap is widening.

The structural read: AI as a capital-allocation test

Step back from either name. The wider earnings calendar this week, including BHP's record full-year output and an H2 2026 profit jump driven by copper, makes a quieter point. Resources companies are being rewarded for what they have already dug out of the ground. Healthtech names are being rewarded for what they have already billed. The companies still talking about what they plan to do, no matter how credible the plan, are paying for the privilege of telling the story.

That is the structural shift. The window in which announcing an AI strategy moved the share price has closed for the Australian healthtech cohort. It is a pattern that rhymes with what earlier software cycles did to incumbents who arrived late: the late movers are forced to overspend to catch up, and the overspend is what the market punishes when revenue does not arrive on schedule. Cogstate's AI investment line is the visible form of that overspend.

The counter-reading is straightforward and deserves airtime: this could simply be a noisy quarter, and the bookings number may convert into revenue over the next four to six periods in line with management's guidance. Investors who sold the print are betting that conversion takes longer, or comes at lower margins, than the bull case implies. Investors who bought the deck are betting the opposite. The transcripts leave that argument unresolved.

What to watch from here

Three dates matter. First, Cogstate's next quarterly update, where the bookings-to-revenue conversion will be tested against fresh guidance. Second, Pro Medicus's full-year close, where the question becomes whether the H2 run-rate holds or steps down. Third, the broader peer set's next reporting cycle, which will tell us whether the market is discriminating between AI-led healthtech names or is rotating out of the category entirely.

The uncomfortable position to hold, and the one this publication leans toward, is that the market has stopped underwriting AI ambition in healthtech and started underwriting AI execution. Pro Medicus cleared that bar this week. Cogstate did not. The 12.4% spread between their share-price moves on 18 August 2026 is the visible price of that distinction.

Desk note: this publication framed the prints as an investor verdict on AI execution rather than a company-quality call. The wire reporting on the day treated each name in isolation; the structural read sits with us.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://www.investing.com/news/company-news/cogstate-fy26-slides-record-contracts-ai-investment-amid-revenue-miss-93CH-4864234
• https://www.investing.com/news/transcripts/earnings-call-transcript-cogstate-posts-strong-fy-2026-growth-but-revenue-miss-weighs-on-shares-93CH-4864228
• https://www.investing.com/news/transcripts/earnings-call-transcript-pro-medicus-posts-record-h2-2026-shares-jump-124-93CH-4864221
• https://www.investing.com/news/stock-market-news/why-is-pro-medicus-stock-surging-today-93CH-4864194
• https://www.investing.com/news/transcripts/earnings-call-transcript-bhp-h2-2026-profit-jumps-as-copper-drives-growth-93CH-4864163